<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03928600</url>
  </required_header>
  <id_info>
    <org_study_id>CES 171-17</org_study_id>
    <nct_id>NCT03928600</nct_id>
  </id_info>
  <brief_title>Labor Induction With a Combined Method (Pharmacologic and Mechanical): Randomized Controlled Trial</brief_title>
  <official_title>Labor Induction With a Combined Method (Pharmacologic and Mechanical): Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Hospitalar De São João, E.P.E.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Hospitalar De São João, E.P.E.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Labor induction is a common pregnancy procedure worldwide. Both mechanical and pharmacologic&#xD;
      agents are used for induction of labor. These agents reduce the incidence of cesarean&#xD;
      delivery in women undergoing induction.&#xD;
&#xD;
      Opposite to old studies of cervical ripening, some recent studies have shown promise in&#xD;
      reducing labor time and risk of cesarean delivery with combination methods. The effectiveness&#xD;
      of this procedure is of major clinical importance and has a large impact in our quotidian&#xD;
      practice.&#xD;
&#xD;
      The objective is to compare the effectiveness of a combined new method to current guidelines&#xD;
      of our department&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We designed a randomized trial that will compare two groups: misoprostol-cervical Foley&#xD;
      simultaneously and the current department guidelines (misoprostol alone/dinoprostone alone).&#xD;
&#xD;
      Inclusion criteria: full-term (≥ 37 weeks of gestation), singleton, vertex-&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">February 29, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to delivery</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cesarean delivery rate</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to active labor</measure>
    <time_frame>3 days</time_frame>
    <description>defined as dilation of 6 cm or greater</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of delivery within 12 hours</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of delivery within 24 hours</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean of maternal length of stay</measure>
    <time_frame>average 3 days</time_frame>
    <description>induction to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>indication for cesarean delivery</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite maternal morbidity outcome</measure>
    <time_frame>6 weeks</time_frame>
    <description>third- or fourth-degree perineal laceration, blood transfusion, chorioamnionitis, endometritis, wound infection, venous thromboembolism, hysterectomy, intensive care unit admission or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite of neonatal morbidities</measure>
    <time_frame>30 days</time_frame>
    <description>SDR, neonatal sepsis, blood transfusion, encephalopathy hypoxic-ischemic, intraventricular hemorrhage of grade III/IV</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Labor, Induced</condition>
  <condition>Cervical Ripening</condition>
  <arm_group>
    <arm_group_label>Combined method induction group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 micrograms misoprostol vaginal applied placed along with cervical Foley (team will repeat misoprostol application each 4 hours till 6 doses of misoprostol)&#xD;
After 4 hours of last misoprostol initiate oxytocin.&#xD;
Cervical Foley will be removed after 12h of placement or when fails out.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Current department guidelines group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Following current department guidelines, as usual, with the method considered more suitable.&#xD;
If they opted for vaginal misoprostol, team will insert 25micrograms, repeat application 4/4h, until 150micrograms, after last misoprostol, wait 4 hours before initiating oxytocin.&#xD;
If option is vaginal dinoprostone the insert of 10mg is removed after 24h in place.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Cervical Foley combined with Misoprostol</intervention_name>
    <description>Placement of cervical Foley catheter along with application of vaginal misoprostol 25ug that will be repeated 4/4h until 150ug</description>
    <arm_group_label>Combined method induction group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinoprostone 10mg insert OR</intervention_name>
    <description>Application for 24h of Dinoprostone 10mg insert</description>
    <arm_group_label>Current department guidelines group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Application of vaginal misoprostol 25ug 4/4h until 150ug</description>
    <arm_group_label>Current department guidelines group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  full-term (≥ 37 weeks of gestation)&#xD;
&#xD;
          -  singleton&#xD;
&#xD;
          -  vertex-presenting gestations&#xD;
&#xD;
          -  with no contraindication to vaginal delivery&#xD;
&#xD;
          -  intact membranes&#xD;
&#xD;
          -  Bishop score &lt; 7 and cervical dilation ≤2 cm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contraindication for misoprostol&#xD;
&#xD;
          -  history of previous caesarean&#xD;
&#xD;
          -  rupture of membranes,&#xD;
&#xD;
          -  fetal or maternal morbidities (fetal major abnormalities, FIGO definition of&#xD;
             pathological CTG, HELLP syndrome, preeclampsia or hypertension with severe features,&#xD;
             fetal growth restriction)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rita P Valente, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Hospitalar São João, Porto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Hospitalar São João</name>
      <address>
        <city>Porto</city>
        <zip>4100</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 4, 2019</study_first_submitted>
  <study_first_submitted_qc>April 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2019</study_first_posted>
  <last_update_submitted>March 8, 2020</last_update_submitted>
  <last_update_submitted_qc>March 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Hospitalar De São João, E.P.E.</investigator_affiliation>
    <investigator_full_name>Rita Polónia Valente</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>induction of labor</keyword>
  <keyword>cervical ripening</keyword>
  <keyword>combined methods</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

